Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA, a biotechnology company developing circular RNA-based gene and cell therapy technologies through its proprietary circVec platform, has demonstrated significantly extended RNA half-life and enhanced protein expression compared with conventional mRNA systems. The company’s R&D activities are conducted by its wholly owned subsidiary Circio AB in Stockholm, Sweden.
The board has approved Circio’s 2025 Remuneration Report and Annual Report, including financial statements, ahead of shareholder approval at the AGM on 8 May 2026. Management highlighted 2025 as a transformative year marked by groundbreaking circVec data, a first collaboration with a global pharmaceutical partner and a substantial capital infusion in early 2026, extending the cash runway into 2030 and enabling accelerated development and scaling of its R&D pipeline.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform, designed for efficient biogenesis of multifunctional circular RNA inside target cells, aims to enhance next-generation RNA, DNA and viral therapeutics, with applications in genetic medicine, cell therapy and chronic disease.
Average Trading Volume: 12,935,618
Current Market Cap: NOK1.96B
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.